Results of the first clinical study in humans that combines hyperbaric oxygen pre-treatment with autologous peripheral blood stem cell transplantation

Autologous hematopoietic cell transplantation (Auto-HCT) following high dose chemotherapy has an important role in treating many patients with lymphoma and multiple myeloma. For patients with a variety of lymphomas including Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL), Auto-HCT might potentially be a curative procedure, in addition to improving overall survival (OS) and progression free survival (PFS) [1-5]. For multiple myeloma, Auto-HCT is not curative, but its role is well-established as a consolidation treatment to achieve deep durable remissions in the majority of patients [6-9].

Source: Biology of Blood and Marrow Transplantation - June 2, 2019 Category: Hematology Authors: Haitham Abdelhakim, Leyla Shune, Sajjad Bhatti, Amy Rose Cantilena, Andrea Baran, Tara L. Lin, Siddhartha Ganguly, Anurag K. Singh, Sunil Abhyankar, Clint Divine, Brea Lipe, Joseph McGuirk, Dennis Allin, Omar S. Aljitawi Source Type: research